The company has developed a technology platform for genetic mutation detection by next-generation sequencing, using proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. Their next-generation sequencing-based gene fusion detection assays utilize fusion detection technology with a lyophilized workflow and an advanced analysis pipeline to detect fusions and mutations, enabling researchers to detect and identify fusion partners of assay genes as well as selected indels and point mutations without prior knowledge of fusion partners or breakpoints. In December 2022, ArcherDX was acquired by Integrated DNA Technologies, Inc. (IDT), which will integrate its portfolio with the acquired NGS research assays to empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries.